Simulations Plus, Inc SLP reported third-quarter fiscal 2024 adjusted earnings (excluding the impact of acquisition costs) of 19 cents per share, which declined 9.5% on a year-over-year basis. The figure, however, topped the Zacks Consensus Estimate by 18.8%. The top line increased 14% year over year to $18.5 million, primarily due to higher software revenues in the Clinical Pharmacology & Pharmacometrics (CPP) and Cheminformatics business units. Continued momentum seen in ADMET Predictor and MonolixSuite platforms was another driver. The top line beat the Zacks Consensus Estimate by 3.4%. SLP has also opted to discontinue the quarterly cash dividend and redirect these funds towards growth initiatives to boost long-term shareholder value. The last dividend of 6 cents per share will be disbursed on Aug 5, 2024, to shareholders on record as of Jul 29, 2024. In the past year, SLP's shares have lost 3.4% compared with the sub-industry’s growth of 31.2%. Zacks Investment Research Image Source: Zacks Investment Research Quarter in Details Fiscal third-quarter revenues from Software (64% of total quarterly revenues) increased 12% year over year to $11.9 million. Sales of MonolixSuite were up 13%. GastroPlus and ADMET Predictor offerings sales saw an increase of 7% and 15% year over year, respectively. The renewal rate for commercial customers came in at 93% (based upon fees) and 86% (based on accounts) compared with 96% and 87% in the prior quarter, respectively. Services’ revenues (36%) improved 18% to $6.6 million. The segment’s top line gained from higher revenues from Quantitative Systems Pharmacology (QSP) and Clinical Pharmacology & Pharmacometrics (CPP) business units. Sales of PBPK unit were down 10% as the temporary delays in acquiring client source data deferred the initiation of contracted projects. QSP and CPP sales saw an increase of 49% and 27% year over year, respectively. QSP unit is gaining from increasing immunology and cancer model projects. Services’ backlog was $19.6 million at the end of the reported quarter, up 24.8% year over year. Operating Details The gross margin in the quarter under review was 71% compared with 82% in the prior-year quarter. The Software segment’s gross margin came in at 88% compared with 91% in the prior-year quarter. Services’ gross margin was 41%, down from 63%. Total operating expenses, as a percentage of revenues, were 61% compared with 57% a year ago. The operating income margin was 10% compared with 25% a year ago. Adjusted EBITDA margin came in at 31%, a decrease from 40% prior-year quarter. Balance Sheet As of May 31, 2024, cash and short-term investments were $119 million compared with $108.5 million as of Feb 29, 2024. Outlook For fiscal 2024, Simulations Plus expects revenues to be between $69 million and $72 million. This suggests an increase of 15-20% from fiscal 2023 revenues. Earlier, the company had projected revenues to be in the range of $66-$69 million. The company expects $3 million in revenue contribution from the Pro-ficiency Holdings acquisition and the creation of the new Clinical Simulations and Medical Communications business segment. The company projects Software and Services to comprise 55-60% and 40-45% of revenues, respectively. SLP estimates adjusted earnings per share to be between 54 cents and 56 cents. SLP estimates GAAP EPS to be between 46-48 cents compared with the earlier guided range of 66-68 cents per share. The company’s GAAP numbers include the impact of acquisition-related charges. Currently, Simulations Plus carries a Zacks Rank #4 (Sell). Stocks to Consider Some better-ranked stocks worth consideration in the broader technology space are NVIDIA Corporation NVDA, Arista Networks, Inc. ANET and Woodward, Inc. WWD. While NVDA and WWD sport a Zacks Rank #1 (Strong Buy) each, ANET carries a Zacks Rank of 2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for NVDA’s fiscal 2024 EPS is pegged at $2.68. The long-term earnings growth rate is 37.6%. NVDA’s earnings beat the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 18.4%. Shares of NVDA have soared 189.2% in the past year. The Zacks Consensus Estimate for WWD’s fiscal 2024 EPS has increased 6.5% in the past 60 days to $5.88. Woodward’s earnings beat the Zacks Consensus Estimate in all of the last four quarters. The average earnings surprise is 26.1%. Shares of WWD have soared 45.5% in the past year. The Zacks Consensus Estimate for ANET’s 2024 EPS is pegged at $7.92, indicating growth of 14.1% from the year-ago levels. ANET’s earnings beat the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 15.4%. The long-term earnings growth rate is 16.1%. Shares of ANET have rallied 123.2% in the past year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NVIDIA Corporation (NVDA):Free Stock Analysis Report Simulations Plus, Inc. (SLP):Free Stock Analysis Report Woodward, Inc. (WWD):Free Stock Analysis Report Arista Networks, Inc. (ANET):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Simulations Plus (SLP) Q3 Earnings & Revenues Beat Estimates
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...